![Madhav Devalaraja](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Madhav Devalaraja
Gründer bei Corvidia Therapeutics, Inc.
Aktive Beziehungen
Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
---|---|---|---|---|
Harish Dave | M | 66 |
AUM Biosciences Ltd.
![]() AUM Biosciences Ltd. BiotechnologyHealth Technology Aum Biosciences Ltd. is a global clinical-stage oncology. It is focused on advancing a pipeline of precision oncology therapeutics designed to deploy multi-faceted inhibition strategies to reverse cancer resistance. The company was founded on October 28, 2022 and is headquartered in George Town, Cayman Islands.
AUM Biosciences Pte Ltd.
![]() AUM Biosciences Pte Ltd. Miscellaneous Commercial ServicesCommercial Services Part of AUM Biosciences Ltd., AUM Biosciences Pte Ltd. is a clinical-stage biotech company based in Singapore, Singapore. The Singaporean company focuses on discovering and developing novel targeted oncology therapies, particularly for cancers with a clear genetic marker. AUM Biosciences has an extensive track record of selecting distinctive early-stage assets, successfully exiting virtual biotech models, and contributing significantly to the development of several currently marketed oncology treatments with annual peak sales up to $3 billion. AUM Biosciences is advancing a broad portfolio of precision oncology therapeutics, including AUM001, AUM601, and AUM302, which have entered clinical trials and received orphan drug designation from the FDA for the treatment of various cancers. The company was founded by Harish Dave and is currently led by CEO Vishal Doshi. | 2 Jahre |
Ross Horsburgh | M | 69 |
AUM Biosciences Ltd.
![]() AUM Biosciences Ltd. BiotechnologyHealth Technology Aum Biosciences Ltd. is a global clinical-stage oncology. It is focused on advancing a pipeline of precision oncology therapeutics designed to deploy multi-faceted inhibition strategies to reverse cancer resistance. The company was founded on October 28, 2022 and is headquartered in George Town, Cayman Islands.
AUM Biosciences Pte Ltd.
![]() AUM Biosciences Pte Ltd. Miscellaneous Commercial ServicesCommercial Services Part of AUM Biosciences Ltd., AUM Biosciences Pte Ltd. is a clinical-stage biotech company based in Singapore, Singapore. The Singaporean company focuses on discovering and developing novel targeted oncology therapies, particularly for cancers with a clear genetic marker. AUM Biosciences has an extensive track record of selecting distinctive early-stage assets, successfully exiting virtual biotech models, and contributing significantly to the development of several currently marketed oncology treatments with annual peak sales up to $3 billion. AUM Biosciences is advancing a broad portfolio of precision oncology therapeutics, including AUM001, AUM601, and AUM302, which have entered clinical trials and received orphan drug designation from the FDA for the treatment of various cancers. The company was founded by Harish Dave and is currently led by CEO Vishal Doshi. | 2 Jahre |
Arjun Oberoi | M | 51 |
AUM Biosciences Ltd.
![]() AUM Biosciences Ltd. BiotechnologyHealth Technology Aum Biosciences Ltd. is a global clinical-stage oncology. It is focused on advancing a pipeline of precision oncology therapeutics designed to deploy multi-faceted inhibition strategies to reverse cancer resistance. The company was founded on October 28, 2022 and is headquartered in George Town, Cayman Islands.
AUM Biosciences Pte Ltd.
![]() AUM Biosciences Pte Ltd. Miscellaneous Commercial ServicesCommercial Services Part of AUM Biosciences Ltd., AUM Biosciences Pte Ltd. is a clinical-stage biotech company based in Singapore, Singapore. The Singaporean company focuses on discovering and developing novel targeted oncology therapies, particularly for cancers with a clear genetic marker. AUM Biosciences has an extensive track record of selecting distinctive early-stage assets, successfully exiting virtual biotech models, and contributing significantly to the development of several currently marketed oncology treatments with annual peak sales up to $3 billion. AUM Biosciences is advancing a broad portfolio of precision oncology therapeutics, including AUM001, AUM601, and AUM302, which have entered clinical trials and received orphan drug designation from the FDA for the treatment of various cancers. The company was founded by Harish Dave and is currently led by CEO Vishal Doshi. | 2 Jahre |
Vishal Doshi | M | 38 |
AUM Biosciences Ltd.
![]() AUM Biosciences Ltd. BiotechnologyHealth Technology Aum Biosciences Ltd. is a global clinical-stage oncology. It is focused on advancing a pipeline of precision oncology therapeutics designed to deploy multi-faceted inhibition strategies to reverse cancer resistance. The company was founded on October 28, 2022 and is headquartered in George Town, Cayman Islands.
AUM Biosciences Pte Ltd.
![]() AUM Biosciences Pte Ltd. Miscellaneous Commercial ServicesCommercial Services Part of AUM Biosciences Ltd., AUM Biosciences Pte Ltd. is a clinical-stage biotech company based in Singapore, Singapore. The Singaporean company focuses on discovering and developing novel targeted oncology therapies, particularly for cancers with a clear genetic marker. AUM Biosciences has an extensive track record of selecting distinctive early-stage assets, successfully exiting virtual biotech models, and contributing significantly to the development of several currently marketed oncology treatments with annual peak sales up to $3 billion. AUM Biosciences is advancing a broad portfolio of precision oncology therapeutics, including AUM001, AUM601, and AUM302, which have entered clinical trials and received orphan drug designation from the FDA for the treatment of various cancers. The company was founded by Harish Dave and is currently led by CEO Vishal Doshi. | 2 Jahre |
John Patava | M | 59 |
AUM Biosciences Ltd.
![]() AUM Biosciences Ltd. BiotechnologyHealth Technology Aum Biosciences Ltd. is a global clinical-stage oncology. It is focused on advancing a pipeline of precision oncology therapeutics designed to deploy multi-faceted inhibition strategies to reverse cancer resistance. The company was founded on October 28, 2022 and is headquartered in George Town, Cayman Islands.
AUM Biosciences Pte Ltd.
![]() AUM Biosciences Pte Ltd. Miscellaneous Commercial ServicesCommercial Services Part of AUM Biosciences Ltd., AUM Biosciences Pte Ltd. is a clinical-stage biotech company based in Singapore, Singapore. The Singaporean company focuses on discovering and developing novel targeted oncology therapies, particularly for cancers with a clear genetic marker. AUM Biosciences has an extensive track record of selecting distinctive early-stage assets, successfully exiting virtual biotech models, and contributing significantly to the development of several currently marketed oncology treatments with annual peak sales up to $3 billion. AUM Biosciences is advancing a broad portfolio of precision oncology therapeutics, including AUM001, AUM601, and AUM302, which have entered clinical trials and received orphan drug designation from the FDA for the treatment of various cancers. The company was founded by Harish Dave and is currently led by CEO Vishal Doshi. | 5 Jahre |
Sylvie Grégoire | M | 62 |
Corvidia Therapeutics, Inc.
![]() Corvidia Therapeutics, Inc. BiotechnologyHealth Technology Corvidia Therapeutics, Inc. is a biotechnology company focusing on cardiovascular therapies. It develops treatments for atherosclerotic cardiovascular disease, inflammation in chronic kidney diseases, and high triglyceride-induced acute pancreatitis. The company was founded by Michael H. Davidson, Rahul Kakkar, Matt Devalaraja, and Ram Aiyar in 2015 and is headquartered in Waltham, MA. | 8 Jahre |
Alexander G. Asam | M | 58 |
Corvidia Therapeutics, Inc.
![]() Corvidia Therapeutics, Inc. BiotechnologyHealth Technology Corvidia Therapeutics, Inc. is a biotechnology company focusing on cardiovascular therapies. It develops treatments for atherosclerotic cardiovascular disease, inflammation in chronic kidney diseases, and high triglyceride-induced acute pancreatitis. The company was founded by Michael H. Davidson, Rahul Kakkar, Matt Devalaraja, and Ram Aiyar in 2015 and is headquartered in Waltham, MA. | - |
Graziano Seghezzi | M | 55 |
Corvidia Therapeutics, Inc.
![]() Corvidia Therapeutics, Inc. BiotechnologyHealth Technology Corvidia Therapeutics, Inc. is a biotechnology company focusing on cardiovascular therapies. It develops treatments for atherosclerotic cardiovascular disease, inflammation in chronic kidney diseases, and high triglyceride-induced acute pancreatitis. The company was founded by Michael H. Davidson, Rahul Kakkar, Matt Devalaraja, and Ram Aiyar in 2015 and is headquartered in Waltham, MA. | - |
Paul Eisenberg | M | - |
Corvidia Therapeutics, Inc.
![]() Corvidia Therapeutics, Inc. BiotechnologyHealth Technology Corvidia Therapeutics, Inc. is a biotechnology company focusing on cardiovascular therapies. It develops treatments for atherosclerotic cardiovascular disease, inflammation in chronic kidney diseases, and high triglyceride-induced acute pancreatitis. The company was founded by Michael H. Davidson, Rahul Kakkar, Matt Devalaraja, and Ram Aiyar in 2015 and is headquartered in Waltham, MA. | - |
Tyrell J. Rivers | M | 51 |
Corvidia Therapeutics, Inc.
![]() Corvidia Therapeutics, Inc. BiotechnologyHealth Technology Corvidia Therapeutics, Inc. is a biotechnology company focusing on cardiovascular therapies. It develops treatments for atherosclerotic cardiovascular disease, inflammation in chronic kidney diseases, and high triglyceride-induced acute pancreatitis. The company was founded by Michael H. Davidson, Rahul Kakkar, Matt Devalaraja, and Ram Aiyar in 2015 and is headquartered in Waltham, MA. | - |
John Trainer | M | 50 |
Corvidia Therapeutics, Inc.
![]() Corvidia Therapeutics, Inc. BiotechnologyHealth Technology Corvidia Therapeutics, Inc. is a biotechnology company focusing on cardiovascular therapies. It develops treatments for atherosclerotic cardiovascular disease, inflammation in chronic kidney diseases, and high triglyceride-induced acute pancreatitis. The company was founded by Michael H. Davidson, Rahul Kakkar, Matt Devalaraja, and Ram Aiyar in 2015 and is headquartered in Waltham, MA. | - |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Ehemalige Beziehungen
Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
---|---|---|---|---|
Michael Davidson | M | 67 |
Corvidia Therapeutics, Inc.
![]() Corvidia Therapeutics, Inc. BiotechnologyHealth Technology Corvidia Therapeutics, Inc. is a biotechnology company focusing on cardiovascular therapies. It develops treatments for atherosclerotic cardiovascular disease, inflammation in chronic kidney diseases, and high triglyceride-induced acute pancreatitis. The company was founded by Michael H. Davidson, Rahul Kakkar, Matt Devalaraja, and Ram Aiyar in 2015 and is headquartered in Waltham, MA. | 4 Jahre |
Rahul Kakkar | M | 49 |
Corvidia Therapeutics, Inc.
![]() Corvidia Therapeutics, Inc. BiotechnologyHealth Technology Corvidia Therapeutics, Inc. is a biotechnology company focusing on cardiovascular therapies. It develops treatments for atherosclerotic cardiovascular disease, inflammation in chronic kidney diseases, and high triglyceride-induced acute pancreatitis. The company was founded by Michael H. Davidson, Rahul Kakkar, Matt Devalaraja, and Ram Aiyar in 2015 and is headquartered in Waltham, MA. | 4 Jahre |
Ram Aiyar | M | - |
Corvidia Therapeutics, Inc.
![]() Corvidia Therapeutics, Inc. BiotechnologyHealth Technology Corvidia Therapeutics, Inc. is a biotechnology company focusing on cardiovascular therapies. It develops treatments for atherosclerotic cardiovascular disease, inflammation in chronic kidney diseases, and high triglyceride-induced acute pancreatitis. The company was founded by Michael H. Davidson, Rahul Kakkar, Matt Devalaraja, and Ram Aiyar in 2015 and is headquartered in Waltham, MA. | 5 Jahre |
Marc M. P. de Garidel | M | 66 |
Corvidia Therapeutics, Inc.
![]() Corvidia Therapeutics, Inc. BiotechnologyHealth Technology Corvidia Therapeutics, Inc. is a biotechnology company focusing on cardiovascular therapies. It develops treatments for atherosclerotic cardiovascular disease, inflammation in chronic kidney diseases, and high triglyceride-induced acute pancreatitis. The company was founded by Michael H. Davidson, Rahul Kakkar, Matt Devalaraja, and Ram Aiyar in 2015 and is headquartered in Waltham, MA. | 2 Jahre |
Preston Klassen | M | 55 |
Corvidia Therapeutics, Inc.
![]() Corvidia Therapeutics, Inc. BiotechnologyHealth Technology Corvidia Therapeutics, Inc. is a biotechnology company focusing on cardiovascular therapies. It develops treatments for atherosclerotic cardiovascular disease, inflammation in chronic kidney diseases, and high triglyceride-induced acute pancreatitis. The company was founded by Michael H. Davidson, Rahul Kakkar, Matt Devalaraja, and Ram Aiyar in 2015 and is headquartered in Waltham, MA. | - |
Aaron Kantoff | M | 29 |
Corvidia Therapeutics, Inc.
![]() Corvidia Therapeutics, Inc. BiotechnologyHealth Technology Corvidia Therapeutics, Inc. is a biotechnology company focusing on cardiovascular therapies. It develops treatments for atherosclerotic cardiovascular disease, inflammation in chronic kidney diseases, and high triglyceride-induced acute pancreatitis. The company was founded by Michael H. Davidson, Rahul Kakkar, Matt Devalaraja, and Ram Aiyar in 2015 and is headquartered in Waltham, MA. | 3 Jahre |
Douglas Kling | M | 50 |
Corvidia Therapeutics, Inc.
![]() Corvidia Therapeutics, Inc. BiotechnologyHealth Technology Corvidia Therapeutics, Inc. is a biotechnology company focusing on cardiovascular therapies. It develops treatments for atherosclerotic cardiovascular disease, inflammation in chronic kidney diseases, and high triglyceride-induced acute pancreatitis. The company was founded by Michael H. Davidson, Rahul Kakkar, Matt Devalaraja, and Ram Aiyar in 2015 and is headquartered in Waltham, MA. | 4 Jahre |
Adrien Lemoine | M | - |
Corvidia Therapeutics, Inc.
![]() Corvidia Therapeutics, Inc. BiotechnologyHealth Technology Corvidia Therapeutics, Inc. is a biotechnology company focusing on cardiovascular therapies. It develops treatments for atherosclerotic cardiovascular disease, inflammation in chronic kidney diseases, and high triglyceride-induced acute pancreatitis. The company was founded by Michael H. Davidson, Rahul Kakkar, Matt Devalaraja, and Ram Aiyar in 2015 and is headquartered in Waltham, MA. | - |
Karim Helmy | M | - |
Corvidia Therapeutics, Inc.
![]() Corvidia Therapeutics, Inc. BiotechnologyHealth Technology Corvidia Therapeutics, Inc. is a biotechnology company focusing on cardiovascular therapies. It develops treatments for atherosclerotic cardiovascular disease, inflammation in chronic kidney diseases, and high triglyceride-induced acute pancreatitis. The company was founded by Michael H. Davidson, Rahul Kakkar, Matt Devalaraja, and Ram Aiyar in 2015 and is headquartered in Waltham, MA. | 1 Jahre |
Lina Gugucheva | F | 37 |
Corvidia Therapeutics, Inc.
![]() Corvidia Therapeutics, Inc. BiotechnologyHealth Technology Corvidia Therapeutics, Inc. is a biotechnology company focusing on cardiovascular therapies. It develops treatments for atherosclerotic cardiovascular disease, inflammation in chronic kidney diseases, and high triglyceride-induced acute pancreatitis. The company was founded by Michael H. Davidson, Rahul Kakkar, Matt Devalaraja, and Ram Aiyar in 2015 and is headquartered in Waltham, MA. | 4 Jahre |
Statistik
Land | Beziehungen | % des Gesamten |
---|---|---|
Vereinigte Staaten | 16 | 76,19% |
Cayman Islands | 5 | 23,81% |
Singapur | 5 | 23,81% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
- Börse
- Insiders
- Madhav Devalaraja
- Persönliches Netzwerk